An educational guide to QALYs and ICERs, the core metrics in health economics. Learn how they measure value and guide cost-effectiveness decisions. Updated April 2026 with NICE's new £25k–£35k/QALY threshold.
An in-depth comparison of ICER (US) vs NICE (UK). Explore their methods, QALY thresholds, and how they assess drug value to influence global pricing floors.
Updated April 2026: Million-dollar gene therapy pricing analysis covering Casgevy, Lyfgenia, Lenmeldy, Elevidys (with 2025 safety update), the Roctavian and Beqvez market withdrawals, and CMS's 2025 Cell and Gene Therapy Access Model. Compares one-time cure costs to lifetime chronic care using value-based pricing, ICER QALY thresholds, and outcomes-based contracts.
Learn how patient quality of life (QoL) data is quantified into Quality-Adjusted Life Years (QALYs) to perform cost-effectiveness analysis for specialty drugs.
© 2026 IntuitionLabs. All rights reserved.
